Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
Recruiting · NCT07201012 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Hospitalier Universitaire de Nīmes
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.
Who can take part
Inclusion criteria
- Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).
- Patient followed at Nîmes University Hospital.
- Patient having given free and informed consent.
- Person affiliated to or benefiting from a social security scheme.
Exclusion criteria
- Person under court protection, guardianship or curatorship.
- A person who is unable to give consent.
- Person for whom it is impossible to give informed information.
Where it is running
1 location listed.
- CHU de Nîmes - Nîmes, Gard, France